Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs METRO I.V. IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Mild to moderate pain,Fever
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
<20% bound to plasma proteins
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
100% intravenous
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs METRO I.V. IN PLASTIC CONTAINER, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and METRO I.V. IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and METRO I.V. IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.